Division of Caladrius Biosciences Inc.
Latest From NeoStem
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014.
China's Suzhou Erye Pharmaceutical generics maker is losing its majority stakeholder, as U.S.-based NeoStem offers its 51% stake for sale for $12.3 million.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Caladrius Biosciences Inc.
- Senior Management
Denis Rodgerson, PhD, Pres. & CEO
Larry May, CFO
Simon Lam, VP, Bus. Dev.
Brad Maroni, MD, VP, Clinical Dev.
Edward Garnett, VP, Sales & Mktg.
- Contact Info
Phone: (818) 991-8770
28720 Canwood St.
Agoura Hills, CA 91301
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.